GBLX
GB Sciences, Inc. [GBLX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GBLX Stock Summary
In the News
GBLX Financial details
Company Rating
-
Market Cap
2.56M
Income
-6.03M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
12 Feb 2024
P/E
-0.36
Forward P/E
-
PEG
0.01
P/S
-
P/B
-0.48
P/C
-
P/FCF
-2.02
Quick Ratio
0.02
Current Ratio
0.05
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
-141470869.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
822.69%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-54.55%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-2706%
ROE
165%
ROC
0.38%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.006-0.02
52W High
-
52W Low
-
RSI
47.77
Rel Volume
0.33
Avg Volume
125.6K
Volume
40.91K
Perf Week
-14.44%
Perf Month
-16.3%
Perf Quarter
-45%
Perf Half Y
-45%
-
-
-
-
Beta
0.352
-
-
Volatility
0%, 0%
Prev Close
4.05%
Price
0.00385
Change
10%
Company Profile
- Volume Average 125.6K
- Market Capitalization 2.56M
- Employee 3
- CEO Mr. John Claybron Poss
- Headquarters Las Vegas,NV,US
- IPO Date 2008-05-12
-
Website
https://www.gbsciences.com 
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
